1977030D.AX

Novotech and Endpoints Present "Evolution of Cell & Gene Therapy in China: The Case for Universal CAR-T"

Retrieved on: 
星期一, 七月 18, 2022
Global Data Synchronization Network, Drug development, Technology, Compliance, Cros, Ownership, Investment, Asia-Pacific Telecentre Network, CRO, Pharmaceutical industry, Fine chemical

The APAC region was the largest contributor, with more than 50% of the trials followed by the US (29%) and the EU5 (17%).

Key Points: 
  • The APAC region was the largest contributor, with more than 50% of the trials followed by the US (29%) and the EU5 (17%).
  • Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases.
  • It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas.
  • Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US.

Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea

Retrieved on: 
星期三, 七月 13, 2022
Clinical trial, GSK, IVI, Vaccine, CEPI, Severe acute respiratory syndrome coronavirus 2, Korean Ministry of Culture, CRO, Hepatitis B, CEO, Bill, SK, Government, Coalition, COVID-19, IPD, AstraZeneca, International Vaccine Institute, Asia-Pacific, University of Washington School of Medicine, Epidemic, Research, Pandemic, University, HPV, Drug development, Institute, Pharmaceutical industry, Phase, Food

SEOUL, S.KOREA, July 13, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, congratulates its client SK bioscience on the recent COVID-19 vaccine licence approval.

Key Points: 
  • SEOUL, S.KOREA, July 13, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, congratulates its client SK bioscience on the recent COVID-19 vaccine licence approval.
  • South Korea has become one of the few countries in the world to have both a domestically developed COVID-19 vaccine and a treatment.
  • Dr. John Moller, CEO Novotech said, "As the lead CRO managing the Phase lll study in six APAC countries, the entire team at Novotech congratulates SK bioscience for such an outstanding clinical success and subsequent licence approval.
  • We look forward to working with SK bioscience on further vaccine developments in the near future."